Freeline Therapeutics Holdings plc (FRLN)の価格はいくらですか

Freeline Therapeutics Holdings plc (FRLN)の価格は$6.48です

Freeline Therapeutics Holdings plc (FRLN)の時価総額は何ですか

Freeline Therapeutics Holdings plc (FRLN)の時価総額は$15.41Mです

Freeline Therapeutics Holdings plc（FRLN）発行済株式数

Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in its clinical development phase, focused on creating groundbreaking gene therapies. These innovative treatments leverage adeno-associated virus (AAV) vector technology to tackle inherited, systemic, and severely debilitating genetic conditions. The company's leading therapeutic candidate, verbrinacogene setparvovec (FLT180a), is presently undergoing Phase 1/2 clinical trials for the management of hemophilia B in adult males. Furthermore, Freeline's pipeline features FLT190, which is also in Phase 1/2 clinical evaluation for treating Fabry disease, and FLT201, a gene therapy designed to target the liver for type 1 Gaucher disease, likewise progressing through Phase 1/2 trials. Beyond these specific programs, the company is actively pursuing research initiatives across a range of other systemic gene therapy indications. Freeline was established in 2015 and operates from its headquarters in Stevenage, United Kingdom.

年	発行済株式数	変化
提供された日付のデータは十分ではありません。

年

発行済株式数

変化

提供された日付のデータは十分ではありません。

企業	発行済株式数	差	国
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	-	US
Argenx SE ARGX.US	62.19M	-	NL
CSL Limited CSL.AX	483.58M	-	AU
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	0.00	-	BE

企業

発行済株式数

差

国